Patents by Inventor Mark Leo Michaels

Mark Leo Michaels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF21 Mutants and Uses Thereof
    Publication number: 20250136653
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 7, 2024
    Publication date: May 1, 2025
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 Mutants and Uses Thereof
    Publication number: 20240076333
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 7, 2024
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, JIng Xu
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11840558
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: December 12, 2023
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 11685770
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 27, 2023
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • FG21 MUTANTS AND USES THEREOF
    Publication number: 20210317176
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 24, 2021
    Publication date: October 14, 2021
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
    Patent number: 10308704
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 4, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS
    Publication number: 20190085054
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Jeonghoon Sun, Jason Charles O'Neill, Randal R. Ketchem, Randy Ira Hecht, Edward J. Belouski, Mark Leo Michaels
  • Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
    Patent number: 10189890
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 29, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Jason Charles O'Neill, Randal R. Ketchem, Randy Ira Hecht, Edward J. Belouski, Mark Leo Michaels
  • FGF21 Mutants and Uses Thereof
    Publication number: 20190023757
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: January 24, 2019
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Methods of treating of diabetes and obesity using FGF21 mutants
    Patent number: 10011642
    Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 3, 2018
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Inhibitory polypeptides specific to WNT inhibitors
    Patent number: 9708375
    Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Amgen Inc.
    Inventors: Ryan B. Case, Benjamin M. Alba, Alice Bakker, Irwin Chen, Amy N. Duguay, Monica Florio, Peng Li, Mark Leo Michaels, Mei-Mei Tsai
  • Stabilized Receptor Polypeptides and Uses Thereof
    Publication number: 20170183391
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 29, 2017
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • Human FGF receptor and ?-Klotho binding proteins
    Patent number: 9517264
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 13, 2016
    Assignee: AMGEN INC.
    Inventors: Roger Fachini, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun
  • FGF21 mutants comprising a mutation at position 98, 171 and/or 180
    Patent number: 9493530
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 15, 2016
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF MUTANTS AND USES THEREOF
    Publication number: 20160168223
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 16, 2016
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Stabilized Receptor Polypeptides and Uses Thereof
    Publication number: 20160137718
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: May 19, 2016
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 9273114
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: March 1, 2016
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas C. Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • FGF mutants with reduced proteolysis and aggregation
    Patent number: 9273106
    Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 1, 2016
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS
    Publication number: 20160031969
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Applicant: AMGEN INC.
    Inventors: Jeonghoon Sun, Jason Charles O'Neill, Randal R. Ketchem, Randy Ira Hecht, Edward J. Belouski, Mark Leo Michaels